CDSCO clears recombinant live attenuated dengue vaccine for ages 4 to 60 years
India has approved its first dengue vaccine, with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga. Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt. Ltd.The vaccine is indicated for the prevention of dengue in individuals 4 to 60 years of age.
- ▪India has approved its first dengue vaccine, with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga.
- ▪Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt.
- ▪Ltd.The vaccine is indicated for the prevention of dengue in individuals 4 to 60 years of age.
The Hindu — Top publishes from India and files mainly under world. We currently carry 7,904 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | The Hindu — Top |
| Canonical URL | https://www.thehindu.com/sci-tech/health/cdsco-clears-recombinant-live-attenuated-dengue-vaccine-for-ages-4-to-60-years/article71247951.ece |
| Publication time | Tue, 21 Jul 2026 11:39:36 +0530 |
| Retrieval time | 2026-07-21T06:42:33.721Z |
| Last seen | 2026-07-21T06:42:33.721Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | NbBGF0H7qW57 |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
India has approved its first dengue vaccine, with the Central Drugs Standard Control Organisation (CDSCO) granting marketing authorisation for the Dengue Tetravalent Vaccine (Live, Attenuated) – Qdenga. Manufactured by Takeda GmbH, Germany, the vaccine will be imported by Takeda Biopharmaceuticals India Pvt. Ltd.The vaccine is indicated for the prevention of dengue in individuals 4 to 60 years of age. “The approval has been granted after a comprehensive scientific evaluation of the vaccine’s quality, safety and efficacy in accordance with the provisions of the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945,” said a statement issued by the Union Health Ministry on Tuesday (July 21, 2026).What is Qdenga?Qdenga is a live, attenuated tetravalent dengue vaccine developed using…
Excerpt limited to ~120 words for fair-use compliance. The full article is at The Hindu — Top.
Discussion
0 commentsMore from The Hindu — Top
